Scientists have found a mutation in stem cell genes, which they claim could be linked to development of leukemia and other cancers. A major finding of a new study is the discovery of a novel DNA mutation in the c-Myb gene Read more…
The California Institute for Regenerative Medicine (CIRM) approved $25M to fund 19 projects intended to overcome immune rejection of transplanted stem cells. Read more…
AlloCure, the developer of an adult stem cell therapy for severe kidney disease, has moved its headquarters from Salt Lake City to Burlington, MA and hired a new President and CEO, Robert Brenner, MD. AlloCure is preparing for Phase 2 Trials in Acute Kidney Injury and has reached an important milestone in their evolution, with the completion of enrollment in a Phase 1 trial in acute kidney injury Read more…
iPierian, a biopharmaceutical company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery closed (7/8/10) a $22M Series B equity financing. Read more…
NIH chief Francis Collins is lobbying Congress to set aside a $500M fund that will give start-up biotechs up to $15M to bankroll clinical trials for new drugs that treat neglected diseases. Read more…
In the Proceedings of the National Academy of Sciences, researchers from UC San Diego reported that they have identified a signaling pathway necessary for stem cells to replicate. Read more…
ISCO.OB and Sankara Nethralaya commenced a collaboration to develop (ISCO’s) CytoCor™ stem cell derived corneal tissue. The goal is to use CytoCor to treat corneal blindness and vision impairment. Read more…
Frozen blood from stored samples can be used to make cells resembling stem cells; opening a potential new and easier source for the valued cells. Read more…
ASTM will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the FDA’s special protocol assessment (SPA) process. Read more…
STEM has entered into an agreement to sell 7M shares of its common stock to Seaside 88, LP (“Seaside”), a private investment partnership, at a price of $0.865 per share, which represents a 12.6% discount to the closing price per share of 6/29/10. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.